MBX Biosciences, Inc. Common Stock (NASDAQ: MBX) is a Healthcare company (Biotechnology) with a market capitalization of $2.6B. The Maz Rating grades it against the other companies in its sector.
MBX Biosciences, Inc. Common Stock's current Maz Rating and its five factor grades are for members: log in to see them.
At $53.10, MBX Biosciences, Inc. Common Stock trades at 5.4x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -34.4%, return on invested capital of -33.7% and a free cash flow yield of -3.8%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 19.58. Over the past 52 weeks the share price ranged from $25.11 to $72.64, with a beta of 0.10.
MBX Biosciences, Inc. Common Stock does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 7 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MBX Biosciences, Inc. Common Stock (MBX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 17.5% / 30% · Interest income / Revenue 392200000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.5% / 33% · Receivables / Mkt Cap (36m) 0.12% / 49% · Interest income / Revenue 392200000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.5% / 33.33% · Receivables / Mkt Cap (24m) 0.12% / 33.33% · Interest income / Revenue 392200000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.05% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 96.6% / 33.33% · Receivables / Avg Assets (4Q) 0.65% / 33.33% · Interest income / Revenue 392200000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 96.2% / 33.33% · (Cash+Recv) / Total Assets 96.8% / 33.33% · Interest income / Revenue 392200000.0% / 5% | Fail |
No. As of September 2026, MBX Biosciences, Inc. Common Stock (MBX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MBX Biosciences, Inc. Common Stock is over the AAOIFI limit on Interest income / Revenue.
About 392200000.0% of each dividend: MBX Biosciences, Inc. Common Stock's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.